The initial public offering (IPO) of Dr Lal PathLabs was subscribed 0.65 times on the first day of three day offering. Majority of the subscriptions came from the Qualified Institutional Buyers(QIBs) as their portion was subscribed nearly 1.22 times. QIBs bid for 28.35 lakh shares against 23.2 lakh reserved for the category.
Retail investors subscribed for 17.41 lakh shares against 40.6 lakh shares reserved for them. Retail book was subscribed 0.43 times.
The company had raised Rs 191 crore by allotting close to 35 lakh shares to anchor investors on monday. List of anchor investors included DB International Asia Ltd, Merrill Lynch Capital Markets Espana S.A , Morgan Stanley Mauritius Company Limited, SBI Magnum Multicap Fund and T Rowe Price International Discovery Fund.
Dr. Lal PathLabs is a provider of diagnostics and related healthcare tests and services in India. The New Delhi based company has a catalogue of 1,110 test panels, 1,934 pathology tests and 1,561 radiology and cardiology tests to undertake the entire gamut of routine and specialized tests. Customers include individual patients, companies and institutions, healthcare providers as well as hospital and clinical labs.
Alkem subscribed 0.35 times
Alkem Laboratories IPO was subscribed 0.35 times on day one of the three-day public issue. While the qualified institutional buyers (QIBs) portion was subscribed 0.41 times, the retail portion was subscribed 0.44 times.
The company had raised over Rs 395 crore by allotting shares to anchor investors. The allotment was done at Rs 1050 apiece – the upper price band. The mumbai based company plans to raise close to Rs 1,344 crore through the IPO.
Nomura Financial Advisory, Axis Capital, J P Morgan India and Edelweiss Financial Services are the lead book running managers for the issue.